Clinical Trial Update: BCMA-CD19 cCAR T for the Treatment of Refractory Inflammatory Bowel Disease (IBD) [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial update describes BCMA-CD19 cCAR T therapy for refractory inflammatory bowel disease, with trial status NOT_YET_RECRUITING.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Crohn Disease
• Ulcerative Colitis

Drugs mentioned

• BCMA-CD19 cCAR T (BCMA-CD19 chimeric antigen receptor T-cell therapy)

Snippet

Sponsor: iCell Gene Therapeutics | Conditions: Inflammatory Bowel Diseases (IBD) | Phase 1, Phase 2 | Status: NOT_YET_RECRUITING